Kari Keese - Axonics Modulation Chief Officer
| AXNXDelisted Stock | USD 70.98 0.48 0.68% |
Executive
Kari Keese is Chief Officer of Axonics Modulation Technologies
| Age | 39 |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Kari Keese Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kari Keese against Axonics Modulation stock is an integral part of due diligence when investing in Axonics Modulation. Kari Keese insider activity provides valuable insight into whether Axonics Modulation is net buyers or sellers over its current business cycle. Note, Axonics Modulation insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics Modulation'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kari Keese over two months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over two months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over two months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over two months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 |
Axonics Modulation Management Efficiency
Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Axonics Modulation Technologies currently holds 27.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics Modulation has a current ratio of 10.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axonics Modulation's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brent Lalomia | CONMED | 49 | |
| Hollie Foust | CONMED | N/A | |
| Andres Cedron | Orthofix Medical | 44 | |
| Olaf Hedrich | Medtronic PLC | N/A | |
| Daniel Cher | Si Bone | 60 | |
| Chad Patterson | iRhythm Technologies | 43 | |
| Daniel JD | Orthopediatrics Corp | 55 | |
| Jeff Bertolini | Si Bone | N/A | |
| MS MD | iRhythm Technologies | 51 | |
| Sarah Oliker | CONMED | 43 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Philip Kowalczyk | LivaNova PLC | N/A | |
| Dylan John | Neuropace | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Scott Cundy | Medtronic PLC | N/A | |
| Douglas Devine | iRhythm Technologies | 54 | |
| Guy Yoskovitz | Nano X Imaging | 45 | |
| Martha MD | Neuropace | 68 | |
| Michael Pisetsky | Si Bone | 46 | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
Management Performance
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Ford, Chief Commercial Officer | ||
| Danny Dearen, Chief Operating and Financial Officer | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, CEO, Director | ||
| Rinda Sama, Chief Officer | ||
| JD Esq, General VP | ||
| Aaron Pettit, General Officer | ||
| Kari Keese, Chief Officer | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, Vice Relations | ||
| Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 51.11 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 87.22 % | |||
| Number Of Shares Shorted | 3.31 M | |||
| Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Axonics Stock
If you are still planning to invest in Axonics Modulation check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axonics Modulation's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |